ImageneBio, Inc. (IMA)

ImageneBio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023
Revenue	0.8	3.5	7.96
Revenue Growth (YoY)	-89.95%	-56.04%	-
Gross Profit	0.8	3.5	7.96
Selling, General & Admin	17.88	8.39	7.96
Research & Development	29.01	32.11	21.93
Operating Expenses	46.89	40.5	29.89
Operating Income	-46.09	-37	-21.93
Interest & Investment Income	0.03	0.37	1.19
Other Non Operating Income (Expenses)	3.15	0.07	-0.14
Pretax Income	-43.31	-36.56	-20.87
Income Tax Expense	-0.06	0.01	0.28
Net Income	-43.25	-36.57	-21.15
Preferred Dividends & Other Adjustments	10.11	11.82	10.89
Net Income to Common	-53.36	-48.38	-32.04
Shares Outstanding (Basic)	393	391	321
Shares Outstanding (Diluted)	393	391	321
Shares Change (YoY)	22.60%	21.97%	-
EPS (Basic)	-0.14	-0.12	-0.10
EPS (Diluted)	-0.14	-0.12	-0.10
Free Cash Flow	-44.1	-21.32	-18.54
Free Cash Flow Per Share	-0.11	-0.05	-0.06
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-5761.13%	-1057.14%	-275.37%
Profit Margin	-6669.75%	-1382.40%	-402.39%
Free Cash Flow Margin	-5512.63%	-609.11%	-232.83%
EBITDA	-46.07	-35.86	-19.52
EBITDA Margin	-	-	-245.15%
D&A For EBITDA	0.02	1.14	2.41
EBIT	-46.09	-37	-21.93
EBIT Margin	-	-	-275.37%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q